January 22, 2021 8:21am
It’s a short-term ride, pay-up, follow and slow walk the upside
Pre-open indication: 4 SELLs and 7 BUYs
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are DOWN -0.75% (-233 points), S&P futures are DOWN -0.68% (-26 points) and NASDAQ futures are DOWN -0.57% (-76 points)
Stock futures are falling early Friday morning;
European markets were down as investors wandered through coronavirus restrictions and new economic data out of the euro zone;
Asia-Pacific markets fell as Hong Kong saw heavy losses while the MSCI’s (broadest index of Asia-Pacific shares) outside Japan fell 0.92%.
Henry’omics:
The political reality of Washington is starting to impact markets …
As markets headed to close out the record-setting week on a muted note.
Thursday’s evening’s recap: RegMed Investors’ (RMi) closing bell: “slim pickings in the upside. As I stated last night, wait for the reverses, they came today” … https://www.regmedinvestors.com/articles/11733
- The Nasdaq closed UP +73.67 points (+0.55%);
- The IBB closed down -0.89% and XBI closed down -2.17%
- Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with the increased volume of 9 of 25-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.26 points or -1.20% at 21.32;
- Thursday’s percentage (%) of the 9-upside were +0.40% (RENE.L) to +7.04% (BSTG) while the 25-downside ranges from -0.32% (MESO) to-13.49% (CLBS);
January:
- 8 positive, 5 negative closes and 1 holiday, so far
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell:
Biostage (BSTG) closed up +$0.10 to $1.52 with 1,501 shares traded after Wednesday’s +$0.01 to $1.42 with 1,277 shares traded after Tuesday’s +$0.06 to $1.22 with 8,637 shares traded. Reiterating the WHY bottom-line questions:
- Question#1: On WHAT NEWS is the stocks volume improving?
- Question#2: WHY the “push” to “pump” the share pricing; is it related to exercise of the warrants (warrants exercisable for an aggregate of 122,554 shares of common stock) still outstanding;
- Question#3: Does it seem that DST Capital is behind the race to exercise the warrants?
SELL into Offering announcement:
Precigen (PGEN) closed down -$0.27 to $9.14 after a proposed offering announcement with a negative -$0.87 or -9.52% aftermarket indication;
Bounce-back BUYs:
bluebird bio (BLUE) closed down -$1.04 to $46.84 after Wednesday’s-$1.02 to $49.51 and last Friday’s $50.53, with a positive +$0.33 or +0.70% aftermarket indication;
CRISPR Therapeutics (CRSP) closed down -$4.67 to $185.10 after Wednesday’s -$8.52 to $189.77, Tuesday’s -$1.59 to $198.29 and last Friday’s $199.88 with a positive +$1.68 or +0.91% aftermarket indication;
Editas Medicine (EDIT) closed down -$7.97 to $63.79 after the offering was priced at $66.00 with a +$0.71 or +1.11$% aftermarket indication;
Fate Therapeutics (FATE) closed down -$9.34 or -8.57% to $99.67 after Wednesday’s $109.01, Tuesday’s $114.31 and last Friday’s $113.59 with a positive +$0.83 or +0.83% aftermarket indication;
Intellia Therapeutics (NTLA) closed down -$7.97 to $72.59 after Wednesday’s $80.56, Tuesday’s $83.68 and last Friday’s $81.89, and has a positive +$0.91 or +1.25% aftermarket indication;
Ionis Pharmaceuticals (IONS) closed down -$1.27 to $61.27 after Wednesday’s +$1.51 to $62.54 after Tuesday’s -$0.25 to $61.03 and last Friday’s $61.28 with a positive +$1.38 or +2.25% aftermarket indication;
Sangamo Therapeutics (SGMO) closed down -$0.93 to $14.49 and has a positive +$0.11 or +0.76% aftermarket indication;
SELL into Strength:
Vericel (VCEL) closed up +$0.42 to $40.15 after Wednesday’s $39.73, Tuesday’s $38.98 and last Friday’s $39.01 with a positive +$0.65 or +1.62% aftermarket indication;
Caladrius Biosciences (CLBS) closed down -$0.39 to $2.50 after Wednesday’s +$1.26 or +77.30% to $2.89 after Tuesday’s $1.63, Friday’s $1.57 and last Thursday’s $1.56 with a negative -$0.06 or -2.40% aftermarket indication;
The BOTTOM LINE: Bounce back BUYs are needed … especially since Wednesday and Thursday might have less to do with the inauguration than taking advantage of recent performance to lighten-up on appreciators.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
